Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872453 · ClinicalTrials.gov registry record · Phase 2
Acute Treatment Trial in Adult Subjects With Migraines
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,154
- Enrollment target
NCT03872453: Completed Phase 2 study, sponsored by Pfizer.
NCT03872453 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 2,154 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1520% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03872453, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,154 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
Primary Outcome
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.
Interventions
- DRUG Zavegepant
- DRUG Zavegepant matching placebo
- DEVICE Intranasal Aptar Pharma Unit Dose System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,154 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2019-11-11 |
| Phase | Phase 2 |
What the finished NCT03872453 record still lists
NCT03872453 is an interventional study that assigns participants to a tested intervention. Its 2,154 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1520% higher).
The record links to 0 conditions, and to 3 interventions - of which Zavegepant is the first listed.
NCT03872453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03872453 about?
NCT03872453 is a clinical study titled "Acute Treatment Trial in Adult Subjects With Migraines". The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
What is the current status of trial NCT03872453?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,154 participants. The study started on 2019-03-25. Estimated completion is 2019-11-11.
What interventions are being tested in trial NCT03872453?
The interventions under investigation include: Zavegepant (DRUG), Zavegepant matching placebo (DRUG), Intranasal Aptar Pharma Unit Dose System (DEVICE).
Who is sponsoring clinical trial NCT03872453?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03872453's enrollment target sits among peer trials
2,154 8th of 2000 higher than 1,993 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI